We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+35.64%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$291M
AUM Growth
+$25.4M
(+9.6%)
Cap. Flow
-$37.9M
Cap. Flow
% of AUM
-13.02%
Top 10 Holdings %
Top 10 Hldgs %
53.99%
Holding
96
New
7
Increased
8
Reduced
27
Closed
15
Avg Time Held
7.9
quarters
Top 10 Avg Time Held
5.8
quarters
Top 20 Avg Time Held
7.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProQR Therapeutics
PRQR
|
+$6.64M |
| 2 |
Affimed
AFMD
|
+$3.03M |
| 3 |
Neuronetics
STIM
|
+$1.8M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$1.15M |
| 5 |
Kura Oncology
KURA
|
+$1.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$12M |
| 2 |
Wave Life Sciences
WVE
|
+$3.94M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$3.6M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$3.57M |
| 5 |
Ardelyx
ARDX
|
+$2.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.96% |
| 2 | Miscellaneous | 4.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$104M
| $72.4M | 24.84% |
13,680,554
| – | – |
2013 Q2
26 quarters
|
|
|
2
ProQR Therapeutics
PRQR
$212M
| $11M | 3.79% |
1,114,000
+852,479
| +326% | +$6.64M |
2017 Q4
8 quarters
|
|
3
AtriCure
ATRC
$2.93B
| $10.4M | 3.56% |
318,729
| – | – |
2013 Q2
26 quarters
|
|
|
ARQL
4
DELISTED
Arqule Inc
ARQL
| $9.94M | 3.41% |
497,762
-32,500
| -6% | -$377K |
2016 Q4
12 quarters
|
|
5
DELISTED
Blueprint Medicines
BPMC
| $9.87M | 3.39% |
123,218
| – | – |
2016 Q4
12 quarters
|
|
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
| $9.72M | 3.34% |
47,000
-5,509
| -10% | -$1.02M |
2015 Q3
17 quarters
|
|
7
Fate Therapeutics
FATE
$237M
| $9.2M | 3.16% |
470,000
| – | – |
2019 Q2
2 quarters
|
|
8
DELISTED
Sage Therapeutics
SAGE
| $9.01M | 3.09% |
124,806
| – | – |
2017 Q4
8 quarters
|
|
9
DexCom
DXCM
$31.8B
| $7.95M | 2.73% |
145,352
| – | – |
2017 Q3
9 quarters
|
|
10
iShares Biotechnology ETF
IBB
$10.4B
| $7.82M | 2.68% |
64,900
| – | – |
2016 Q4
12 quarters
|
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $6.56M | 2.25% |
61,008
-3,500
| -5% | -$366K |
2016 Q1
15 quarters
|
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
| $6.47M | 2.22% |
267,839
-19,909
| -7% | -$412K |
2014 Q3
21 quarters
|
|
|
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
| $5.57M | 1.91% |
106,749
-36,015
| -25% | -$1.65M |
2015 Q1
19 quarters
|
|
14
Tvardi Therapeutics
TVRD
$13.3M
| $5.29M | 1.82% |
9,126
-1,400
| -13% | -$982K |
2017 Q3
9 quarters
|
|
15
Akebia Therapeutics
AKBA
$204M
| $4.87M | 1.67% |
770,538
-57,500
| -7% | -$273K |
2017 Q1
11 quarters
|
|
|
LMNX
16
DELISTED
Luminex Corp
LMNX
| $4.73M | 1.62% |
204,091
| – | – |
2017 Q3
9 quarters
|
|
|
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.49M | 1.54% |
98,942
+5,000
| +5% | +$236K |
2018 Q1
7 quarters
|
|
18
Cytokinetics
CYTK
$8.71B
| $4.44M | 1.53% |
418,727
| – | – |
2018 Q2
6 quarters
|
|
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.07M | 1.4% |
74,700
-20,300
| -21% | -$1.01M |
2018 Q2
6 quarters
|
|
|
20
Ascendis Pharma A/S
ASND
$14.8B
| $3.91M | 1.34% |
28,100
-32,380
| -54% | -$3.6M |
2015 Q1
19 quarters
|
|
|
YARW
21
Yarrow Bioscience
YARW
$161M
| $3.7M | 1.27% |
222
-16
| -7% | -$267K |
2018 Q2
6 quarters
|
|
22
Xenon Pharmaceuticals
XENE
$3.31B
| $3.26M | 1.12% |
248,854
-81,813
| -25% | -$861K |
2015 Q3
17 quarters
|
|
|
23
DELISTED
Affimed
AFMD
| $3.11M | 1.07% |
+113,356
| New | +$3.03M |
2019 Q4
0 quarters
|
|
|
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
| $2.65M | 0.91% |
438,884
| – | – |
2014 Q3
21 quarters
|
|
|
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $2.61M | 0.89% |
118,314
| – | – |
2018 Q2
6 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, DAFNA Capital Management held 96 positions worth $291M, up 9.6% from $266M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
DAFNA Capital Management withdrew a net $37.9M in Q4 2019, closing 15 positions and reducing 27 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in Affimed worth $3.11M.
- DAFNA Capital Management's largest Q4 2019 buy was Affimed: 113,356 shares worth $3.11M.
- DAFNA Capital Management added most to ProQR Therapeutics in Q4 2019, an estimated $6.64M increase.
- DAFNA Capital Management's biggest Q4 2019 reduction was Wave Life Sciences, cutting an estimated $3.94M.
- DAFNA Capital Management fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $12M.
- DAFNA Capital Management's ten largest holdings make up 54% of its $291M portfolio in Q4 2019.
- DAFNA Capital Management opened 7 new positions and closed 15 in Q4 2019.
- DAFNA Capital Management's portfolio value rose 9.6% quarter-over-quarter to $291M.
Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.